Valeant Pharmaceuticals Inc. is selling its stake in the Vantiv Pharmaceuticals unit
VANCOUVER, British Columbia — Valeant Pharmaceutical Holdings Inc. announced today that it is selling the company’s remaining 19.9% stake in Vantivo Pharmaceuticals Ltd.and its subsidiary, Vantiva Pharmaceuticals, Inc. to Gilead Sciences Inc. and that the sale price is approximately $1.65 per share.Vantive is currently an OTCQX marketer.The transaction was announced by Valeant and Gileads Chairman…